EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 274 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than... April 11, 2024 Daughter Donates Hair to Mother After She Was Diagnosed with Stage... March 3, 2021 How we are working with industry to translate research into real... April 26, 2022 TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... February 16, 2021 Load more HOT NEWS The Nobel Prize winner helping us treat children’s cancers 运动对肺癌患者的益处 Professional Runner and Mom of Two Shares Photo Of Belly Cavity... Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease...
